Literature DB >> 1324650

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

M R Hammerschlag1, K K Qumei, P M Roblin.   

Abstract

The in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycline were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chlamydiacidal concentration for 90% of strains of 0.03 microns/ml. The activity of azithromycin was similar to those of erythromycin and doxycycline, with MICs for 90% of strains of 0.125 to 0.25 microns/ml. However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin. L-Ofloxacin had activity similar to that of ofloxacin, with MICs of 0.125 to 0.5 micron/ml. From the results of this in vitro study, azithromycin and clarithromycin appear to be effective antibiotics that may have a role in the treatment of infections due to C. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324650      PMCID: PMC191624          DOI: 10.1128/AAC.36.7.1573

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  L E Welsh; C A Gaydos; T C Quinn
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

Authors:  K Chirgwin; P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

4.  Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.

Authors:  B A Lipsky; K J Tack; C C Kuo; S P Wang; J T Grayston
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

Review 5.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 6.  Tissue-directed pharmacokinetics.

Authors:  J J Schentag; C H Ballow
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

7.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

8.  The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans.

Authors:  F Fraschini; F Scaglione; G Pintucci; G Maccarinelli; S Dugnani; G Demartini
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

9.  A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.

Authors:  J T Grayston; C C Kuo; S P Wang; J Altman
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245

  9 in total
  40 in total

Review 1.  The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

Authors:  P J Moss; R G Finch
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

Authors:  S Strigl; P M Roblin; T Reznik; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.

Authors:  D N Fish; E Abraham
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

5.  In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Kishimoto; M Nakajima; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model.

Authors:  Ignatius W Fong; Brian Chiu; Esther Viira; Dan Jang; James B Mahony
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors:  M Kimura; T Kishimoto; Y Niki; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 10.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.